Efficacy of continuous venovenous hemodiafiltration in patients with metformin associated lactic acidosis and acute kidney injury
Research article published in Scientific reports (2025)
Abstract
Metformin associated lactic acidosis (MALA) and severe acute kidney injury (AKI) is a life-threatening condition, often requiring renal replacement therapy. However, the optimal renal replacement therapy regimen in this setting remains unclear. Furthermore, limited data exist on the use of regional citrate anticoagulation, as severe hyperlactatemia is associated with increased risk of citrate accumulation. We retrospectively analyzed the medical records of all patients with MALA and severe AKI requiring renal replacement therapy at our hospital between June 2011 and December 2021. All patients were treated with high dose CVVHDF. Anticoagulation was achieved using either heparin or regional citrate anticoagulation. A total of 27 patients with MALA and AKI requiring renal replacement therapy were identified. In all patients, CVVHDF was started within one hour of the diagnosis. Four deaths were recorded, resulting in an overall mortality rate of 14.8%. In the remaining 23 patients (85.2%), we observed the correction of the metabolic disorder and the recovery of renal function that allowed for the discontinuation of dialysis. Mean lactatemia at diagnosis was 12.9 mmol/l (range 7.0-24.0) and mean pH 6.99 (range 6.50-7.22). CVVHDF mean effluent rate was as high as 52.1 ml/kg/h. In thirteen patients regional citrate anticoagulation was safely employed. In our experience, CVVHDF prescribed at the appropriate dose have yielded favorable results, in terms both of patient survival and metabolic control of the disease. Regional citrate anticoagulation can be safely used in selected cases.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta serie de casos retrospectiva unicéntrica de 27 pacientes con acidosis láctica asociada a metformina y lesión renal aguda grave informó que la hemodiafiltración venovenosa continua (CVVHDF) de alta dosis, con anticoagulación con heparin o citrato regional, se asoció con corrección metabólica y recuperación renal en el 85.2% de los pacientes y una mortalidad general del 14.8%. Su relevancia para la hirudoterapia es indirecta y se centra en el tema de la anticoagulación: ilustra cómo los circuitos extracorpóreos requieren una elección cuidadosa del anticoagulante para equilibrar la coagulación frente al sangrado y el riesgo de acumulación de citrato, la misma lógica de riesgo-beneficio que enmarca dónde podrían o no encajar los anticoagulantes derivados de sanguijuelas. La advertencia clara es que se trata de una serie retrospectiva pequeña y no controlada sobre la anticoagulación del circuito de diálisis en pacientes críticamente enfermos — no involucra sanguijuelas ni agentes derivados de sanguijuelas y no ofrece evidencia sobre la eficacia o seguridad de la hirudoterapia.
Citación
Efficacy of continuous venovenous hemodiafiltration in patients with metformin associated lactic acidosis and acute kidney injury.
De et al. · Scientific reports, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026